Cognitive dysfunction in the patient with antiphospholipid antibodies: Considerations for cause and treatment Melanie J. HarrisonLisa D. Ravdin OriginalPaper Pages: 89 - 94
Prevalence of secondary hematologic disorders in the antiphospholipid syndrome: Impact on coagulation risk Sharon L. Kolasinski OriginalPaper Pages: 95 - 99
The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis Ewa OlechJoan T. Merrill OriginalPaper Pages: 100 - 108
Management of the antiphospholipid syndrome Paul DeMarcoInderprit SinghArthur Weinstein OriginalPaper Pages: 114 - 120
T cells and B cells in the pathogenesis of systemic sclerosis: Recent insights and therapeutic opportunities Francesco Del GaldoCarol M. Artlett OriginalPaper Pages: 123 - 130
Microvascular damage in systemic sclerosis: Detection and monitoring with biomarkers Laura K. Hummers OriginalPaper Pages: 131 - 137
Transforming growth factor-β: Recent advances on its role in immune tolerance Martin A. KriegelMing O. LiRichard A. Flavell OriginalPaper Pages: 138 - 144
The role of circulating fibrocytes in fibrosis Timothy E. QuanShawn E. CowperRichard Bucala OriginalPaper Pages: 145 - 150
Nephrogenic systemic fibrosis: An update Shawn E. CowperPhilip J. Boyer OriginalPaper Pages: 151 - 157